Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model

Leukemia

Volumn 29, Issue 3, 2015, Pages 556-566

  Yu, P ^a   Petrus, M N ^a   Ju, W ^a   Zhang, M ^a,b   Conlon, K C ^a   Nakagawa, M ^a   Maeda, M ^c   Bamford, R N ^d   Waldmann, T A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d Transponics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; NOTCH1 RECEPTOR; ROMIDEPSIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG; 2-(((3,5-DIFLUOROPHENYL)ACETYL)AMINO)-N-(1-METHYL-2-OXO-5-PHENYL-2,3-DIHYDRO-1H-1,4-BENZODIAZEPIN-3-YL)PROPANAMIDE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BORONIC ACID DERIVATIVE; DEPSIPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH1 PROTEIN, MOUSE; PYRAZINE DERIVATIVE; SECRETASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; BETA 2-MICROGLOBULIN; BIOMARKERS, TUMOR; BORONIC ACIDS; BORTEZOMIB; DEPSIPEPTIDES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, INBRED NOD; MICE, SCID; NF-KAPPA B; PYRAZINES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84924543060     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.241     Document Type: Article

References (46)

1. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-6480.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7419.
3. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-382.
4. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M et al. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J 2006; 25: 1000-1008.
5. Wilson JJ, Kovall RA. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 2006; 124: 985-996.
6. Radtke F, Schweisguth F, Pear W. The Notch 'gospel'. EMBO Rep 2005; 6: 1120-1125.
7. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
8. Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA 2010; 107: 16619-16624.
9. Karin M, Greten FR. NF-kappaB: linking in flammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
10. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
11. Portis T, Harding JC, Ratner L. The contribution of NF-kappaB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 2001; 98: 1200-1208.
12. Peloponese J, Yeung M, Jeang K-T. Modulation of nuclear factor-kB by human T-cell leukemia virus type 1 tax protein: Implications for oncogenesis and inflammation. Immunol Res 2006; 34 : 1-12.
13. Horie R. NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int Rev Immunol 2007; 26: 269-281.
14. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
15. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827-5834.
16. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92 (15): 1210-1216.
17. Mori N, Matsuda T, Tadano M, Kinjo T, Yamada Y, Tsukasaki K et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell line and primary adult T-cell leukemia cells. J Virol 2004; 78: 4582-4590.
18. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol 1991; 79: 428-437.
19. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
20. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204: 1813-1824.
21. Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia 2014; 28: 278-288.
22. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010; 24: 2014-2022.
23. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210.
24. Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26: 806-813.
25. Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010; 115: 1735-1745.
26. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6:0 347-359.
27. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88: 11-17.
28. Oswald F, Liptay S, Adler G, Schmid RM. NF-κB2 is a putative target gene of activated NOTCH-1 via RBP-Jκ. Mol Cell Biol 1998; 18: 2077-2088.
29. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A et al. Constitutive activation of NF-kB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000; 19: 3337-3348.
30. Guan E, Wang J, Laborda J, Norcross M, Baeuerle PA, Hoffman T. T cell leukemiaassociated human Notch/translocation-associated Notch homologue has IkB-like activity and physically interacts with nuclear factor-kB proteins in T cells. J Exp Med 1996; 183: 2025-2032.
31. Hironaka N, Mochida K, Mori N, Maeda M, Yamamoto N, Yamaoka S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 2004; 6: 266-278.
32. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.
33. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18: 1357-1363.
34. Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr) 2011; 34: 545-551.
35. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116: 406-417.
36. Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011; 118: 6274-6283.
37. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in Mantle cell lymphoma. Clin Cancer Res 2010; 16: 554-565.
38. Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008; 14 : 549-558.
39. LaVoie MJ, Selkoe DJ. The notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J Biol Chem 2003; 278: 34427-34437.
40. Bland CE, Kimberly P, Rand MD. Notch-induced proteolysis and nuclear localization of the Delta ligand. J Biol Chem 2003; 278: 13607-13610.
41. Parks AL, Klueg KM, Stout JR, Muskavitch MA. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 2000; 127: 1373-1385.
42. Yuan Y, Lu X, Chen X, Shao HW, Huang SL. Jagged 1 contributes to the drug resistance of Jurkat cells in contact with human umbilical cord-derived mesenchymal stem cells. Onco Lett 2013; 6: 1000-1016.
43. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-4303.
44. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65: 2353-2363.
45. Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G et al. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 2011; 118: 380-389.
46. Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, Romany C et al. Leukemiaassociated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.